+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PARP (Poly Adp-Ribose Polymerase) Inhibitors Market 2025-2029- Product Image
PARP (Poly Adp-Ribose Polymerase) Inhibitors Market 2025-2029- Product Image
New

PARP (Poly Adp-Ribose Polymerase) Inhibitors Market 2025-2029

  • PDF Icon

    Report

  • 221 Pages
  • June 2025
  • Region: Global
  • TechNavio
  • ID: 5024999
1h Free Analyst Time
REQUEST FREE SAMPLE
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The parp (Poly ADP-Ribose Polymerase) inhibitors market is forecasted to grow by USD 19.53 billion during 2024-2029, accelerating at a CAGR of 22.5% during the forecast period. The report on the parp (Poly ADP-Ribose Polymerase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expanded application of parp inhibitors, ease of administration for treatment of various cancer indications, and increasing patient assistance programs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

The parp (Poly ADP-Ribose Polymerase) inhibitors market is segmented as below:

By Distribution Channel

  • Retail pharmacies
  • Hospital pharmacies
  • Online pharmacies

By End-user

  • Ovarian cancer
  • Breast cancer
  • Others

By Drug Class

  • Olaparib
  • Niraparib
  • Rucaparib
  • Talazoparib
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the extensive ongoing research as one of the prime reasons driving the parp (Poly ADP-Ribose Polymerase) inhibitors market growth during the next few years. Also, growing prevalence of cancer and new research areas in human genes will lead to sizable demand in the market.

The report on the parp (Poly ADP-Ribose Polymerase) inhibitors market covers the following areas:

  • PARP (Poly ADP-Ribose Polymerase) Inhibitors Market sizing
  • PARP (Poly ADP-Ribose Polymerase) Inhibitors Market forecast
  • PARP (Poly ADP-Ribose Polymerase) Inhibitors Market industry analysis
A robust vendor analysis within the report is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading parp (Poly ADP-Ribose Polymerase) inhibitors market vendors that include AbbVie Inc., Allarity Therapeutics Inc., Artios Pharma, AstraZeneca Plc, Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Everest Pharmaceuticals Ltd., GlaxoSmithKline Plc, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Services Inc., Karyopharm Therapeutics Inc., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Repare Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and Zai Lab Ltd. Also, the parp (Poly ADP-Ribose Polymerase) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Distribution Channel
Executive Summary - Chart on Market Segmentation by End-user
Executive Summary - Chart on Market Segmentation by Drug Class
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Market Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
Overview on factors of disruption
2.4 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
3.1 Market ecosystem
Parent Market
Data Table on - Parent Market
3.2 Market characteristics
Market characteristics analysis
3.3 Value chain analysis
Value chain analysis
4 Market Sizing
4.1 Market definition
Offerings of companies included in the market definition
4.2 Market segment analysis
Market segments
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
Chart on Global - Market size and forecast 2024-2029 ($ million)
Data Table on Global - Market size and forecast 2024-2029 ($ million)
Chart on Global Market: Year-over-year growth 2024-2029 (%)
Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitors Market 2019 - 2023
Historic Market Size - Data Table on Global PARP (Poly ADP-Ribose Polymerase) Inhibitors Market 2019 - 2023 ($ million)
5.2 Distribution Channel segment analysis 2019 - 2023
Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
5.3 End-user segment analysis 2019 - 2023
Historic Market Size - End-user Segment 2019 - 2023 ($ million)
5.4 Drug Class segment analysis 2019 - 2023
Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
5.5 Geography segment analysis 2019 - 2023
Historic Market Size - Geography Segment 2019 - 2023 ($ million)
5.6 Country segment analysis 2019 - 2023
Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
6.1 The impact of AI in the global PARP (poly ADP-ribose polymerase) inhibitors market
7 Five Forces Analysis
7.1 Five forces summary
Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Distribution Channel
8.1 Market segments
Chart on Distribution Channel - Market share 2024-2029 (%)
Data Table on Distribution Channel - Market share 2024-2029 (%)
8.2 Comparison by Distribution Channel
Chart on Comparison by Distribution Channel
Data Table on Comparison by Distribution Channel
8.3 Retail pharmacies - Market size and forecast 2024-2029
Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
8.4 Hospital pharmacies - Market size and forecast 2024-2029
Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
8.5 Online pharmacies - Market size and forecast 2024-2029
Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
8.6 Market opportunity by Distribution Channel
Market opportunity by Distribution Channel ($ million)
Data Table on Market opportunity by Distribution Channel ($ million)
9 Market Segmentation by End-user
9.1 Market segments
Chart on End-user - Market share 2024-2029 (%)
Data Table on End-user - Market share 2024-2029 (%)
9.2 Comparison by End-user
Chart on Comparison by End-user
Data Table on Comparison by End-user
9.3 Ovarian cancer - Market size and forecast 2024-2029
Chart on Ovarian cancer - Market size and forecast 2024-2029 ($ million)
Data Table on Ovarian cancer - Market size and forecast 2024-2029 ($ million)
Chart on Ovarian cancer - Year-over-year growth 2024-2029 (%)
Data Table on Ovarian cancer - Year-over-year growth 2024-2029 (%)
9.4 Breast cancer - Market size and forecast 2024-2029
Chart on Breast cancer - Market size and forecast 2024-2029 ($ million)
Data Table on Breast cancer - Market size and forecast 2024-2029 ($ million)
Chart on Breast cancer - Year-over-year growth 2024-2029 (%)
Data Table on Breast cancer - Year-over-year growth 2024-2029 (%)
9.5 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ million)
Data Table on Others - Market size and forecast 2024-2029 ($ million)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
9.6 Market opportunity by End-user
Market opportunity by End-user ($ million)
Data Table on Market opportunity by End-user ($ million)
10 Market Segmentation by Drug Class
10.1 Market segments
Chart on Drug Class - Market share 2024-2029 (%)
Data Table on Drug Class - Market share 2024-2029 (%)
10.2 Comparison by Drug Class
Chart on Comparison by Drug Class
Data Table on Comparison by Drug Class
10.3 Olaparib - Market size and forecast 2024-2029
Chart on Olaparib - Market size and forecast 2024-2029 ($ million)
Data Table on Olaparib - Market size and forecast 2024-2029 ($ million)
Chart on Olaparib - Year-over-year growth 2024-2029 (%)
Data Table on Olaparib - Year-over-year growth 2024-2029 (%)
10.4 Niraparib - Market size and forecast 2024-2029
Chart on Niraparib - Market size and forecast 2024-2029 ($ million)
Data Table on Niraparib - Market size and forecast 2024-2029 ($ million)
Chart on Niraparib - Year-over-year growth 2024-2029 (%)
Data Table on Niraparib - Year-over-year growth 2024-2029 (%)
10.5 Rucaparib - Market size and forecast 2024-2029
Chart on Rucaparib - Market size and forecast 2024-2029 ($ million)
Data Table on Rucaparib - Market size and forecast 2024-2029 ($ million)
Chart on Rucaparib - Year-over-year growth 2024-2029 (%)
Data Table on Rucaparib - Year-over-year growth 2024-2029 (%)
10.6 Talazoparib - Market size and forecast 2024-2029
Chart on Talazoparib - Market size and forecast 2024-2029 ($ million)
Data Table on Talazoparib - Market size and forecast 2024-2029 ($ million)
Chart on Talazoparib - Year-over-year growth 2024-2029 (%)
Data Table on Talazoparib - Year-over-year growth 2024-2029 (%)
10.7 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ million)
Data Table on Others - Market size and forecast 2024-2029 ($ million)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
10.8 Market opportunity by Drug Class
Market opportunity by Drug Class ($ million)
Data Table on Market opportunity by Drug Class ($ million)
11 Customer Landscape
11.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
12.1 Geographic segmentation
Chart on Market share By Geographical Landscape 2024-2029 (%)
Data Table on Market share By Geographical Landscape 2024-2029 (%)
12.2 Geographic comparison
Chart on Geographic comparison
Data Table on Geographic comparison
12.3 North America - Market size and forecast 2024-2029
Chart on North America - Market size and forecast 2024-2029 ($ million)
Data Table on North America - Market size and forecast 2024-2029 ($ million)
Chart on North America - Year-over-year growth 2024-2029 (%)
Data Table on North America - Year-over-year growth 2024-2029 (%)
12.4 Europe - Market size and forecast 2024-2029
Chart on Europe - Market size and forecast 2024-2029 ($ million)
Data Table on Europe - Market size and forecast 2024-2029 ($ million)
Chart on Europe - Year-over-year growth 2024-2029 (%)
Data Table on Europe - Year-over-year growth 2024-2029 (%)
12.5 Asia - Market size and forecast 2024-2029
Chart on Asia - Market size and forecast 2024-2029 ($ million)
Data Table on Asia - Market size and forecast 2024-2029 ($ million)
Chart on Asia - Year-over-year growth 2024-2029 (%)
Data Table on Asia - Year-over-year growth 2024-2029 (%)
12.6 Rest of World (ROW) - Market size and forecast 2024-2029
Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
12.7 US - Market size and forecast 2024-2029
Chart on US - Market size and forecast 2024-2029 ($ million)
Data Table on US - Market size and forecast 2024-2029 ($ million)
Chart on US - Year-over-year growth 2024-2029 (%)
Data Table on US - Year-over-year growth 2024-2029 (%)
12.8 UK - Market size and forecast 2024-2029
Chart on UK - Market size and forecast 2024-2029 ($ million)
Data Table on UK - Market size and forecast 2024-2029 ($ million)
Chart on UK - Year-over-year growth 2024-2029 (%)
Data Table on UK - Year-over-year growth 2024-2029 (%)
12.9 Germany - Market size and forecast 2024-2029
Chart on Germany - Market size and forecast 2024-2029 ($ million)
Data Table on Germany - Market size and forecast 2024-2029 ($ million)
Chart on Germany - Year-over-year growth 2024-2029 (%)
Data Table on Germany - Year-over-year growth 2024-2029 (%)
12.10 Canada - Market size and forecast 2024-2029
Chart on Canada - Market size and forecast 2024-2029 ($ million)
Data Table on Canada - Market size and forecast 2024-2029 ($ million)
Chart on Canada - Year-over-year growth 2024-2029 (%)
Data Table on Canada - Year-over-year growth 2024-2029 (%)
12.11 China - Market size and forecast 2024-2029
Chart on China - Market size and forecast 2024-2029 ($ million)
Data Table on China - Market size and forecast 2024-2029 ($ million)
Chart on China - Year-over-year growth 2024-2029 (%)
Data Table on China - Year-over-year growth 2024-2029 (%)
12.12 France - Market size and forecast 2024-2029
Chart on France - Market size and forecast 2024-2029 ($ million)
Data Table on France - Market size and forecast 2024-2029 ($ million)
Chart on France - Year-over-year growth 2024-2029 (%)
Data Table on France - Year-over-year growth 2024-2029 (%)
12.13 Italy - Market size and forecast 2024-2029
Chart on Italy - Market size and forecast 2024-2029 ($ million)
Data Table on Italy - Market size and forecast 2024-2029 ($ million)
Chart on Italy - Year-over-year growth 2024-2029 (%)
Data Table on Italy - Year-over-year growth 2024-2029 (%)
12.14 Spain - Market size and forecast 2024-2029
Chart on Spain - Market size and forecast 2024-2029 ($ million)
Data Table on Spain - Market size and forecast 2024-2029 ($ million)
Chart on Spain - Year-over-year growth 2024-2029 (%)
Data Table on Spain - Year-over-year growth 2024-2029 (%)
12.15 Japan - Market size and forecast 2024-2029
Chart on Japan - Market size and forecast 2024-2029 ($ million)
Data Table on Japan - Market size and forecast 2024-2029 ($ million)
Chart on Japan - Year-over-year growth 2024-2029 (%)
Data Table on Japan - Year-over-year growth 2024-2029 (%)
12.16 Mexico - Market size and forecast 2024-2029
Chart on Mexico - Market size and forecast 2024-2029 ($ million)
Data Table on Mexico - Market size and forecast 2024-2029 ($ million)
Chart on Mexico - Year-over-year growth 2024-2029 (%)
Data Table on Mexico - Year-over-year growth 2024-2029 (%)
12.17 Market opportunity By Geographical Landscape
Market opportunity By Geographical Landscape ($ million)
Data Tables on Market opportunity By Geographical Landscape ($ million)
13 Drivers, Challenges, and Opportunity/Restraints
13.1 Market drivers
13.2 Market challenges
13.3 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
13.4 Market opportunities/restraints
14 Competitive Landscape
14.1 Overview
14.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
Overview on factors of disruption
14.4 Industry risks
Impact of key risks on business
15 Competitive Analysis
15.1 Companies profiled
Companies covered
15.2 Company ranking index
Company ranking index
15.3 Market positioning of companies
Matrix on companies position and classification
15.4 AbbVie Inc.
AbbVie Inc. - Overview
AbbVie Inc. - Product / Service
AbbVie Inc. - Key news
AbbVie Inc. - Key offerings
SWOT
15.5 Allarity Therapeutics Inc.
Allarity Therapeutics Inc. - Overview
Allarity Therapeutics Inc. - Product / Service
Allarity Therapeutics Inc. - Key offerings
SWOT
15.6 AstraZeneca Plc
AstraZeneca Plc - Overview
AstraZeneca Plc - Product / Service
AstraZeneca Plc - Key news
AstraZeneca Plc - Key offerings
SWOT
15.7 Bayer AG
Bayer AG - Overview
Bayer AG - Business segments
Bayer AG - Key news
Bayer AG - Key offerings
Bayer AG - Segment focus
SWOT
15.8 BeiGene Ltd.
BeiGene Ltd. - Overview
BeiGene Ltd. - Business segments
BeiGene Ltd. - Key offerings
BeiGene Ltd. - Segment focus
SWOT
15.9 Daiichi Sankyo Co. Ltd.
Daiichi Sankyo Co. Ltd. - Overview
Daiichi Sankyo Co. Ltd. - Product / Service
Daiichi Sankyo Co. Ltd. - Key offerings
SWOT
15.10 Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. - Overview
Everest Pharmaceuticals Ltd. - Product / Service
Everest Pharmaceuticals Ltd. - Key offerings
SWOT
15.11 GlaxoSmithKline Plc
GlaxoSmithKline Plc - Overview
GlaxoSmithKline Plc - Business segments
GlaxoSmithKline Plc - Key news
GlaxoSmithKline Plc - Key offerings
GlaxoSmithKline Plc - Segment focus
SWOT
15.12 IMPACT Therapeutics
IMPACT Therapeutics - Overview
IMPACT Therapeutics - Product / Service
IMPACT Therapeutics - Key offerings
SWOT
15.13 Jeil Pharmaceuticals Co. Ltd.
Jeil Pharmaceuticals Co. Ltd. - Overview
Jeil Pharmaceuticals Co. Ltd. - Product / Service
Jeil Pharmaceuticals Co. Ltd. - Key offerings
SWOT
15.14 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
SWOT
15.15 Merck and Co. Inc.
Merck and Co. Inc. - Overview
Merck and Co. Inc. - Business segments
Merck and Co. Inc. - Key news
Merck and Co. Inc. - Key offerings
Merck and Co. Inc. - Segment focus
SWOT
15.16 Ono Pharmaceutical Co. Ltd.
Ono Pharmaceutical Co. Ltd. - Overview
Ono Pharmaceutical Co. Ltd. - Product / Service
Ono Pharmaceutical Co. Ltd. - Key offerings
SWOT
15.17 Pfizer Inc.
Pfizer Inc. - Overview
Pfizer Inc. - Product / Service
Pfizer Inc. - Key news
Pfizer Inc. - Key offerings
SWOT
15.18 Zai Lab Ltd.
Zai Lab Ltd. - Overview
Zai Lab Ltd. - Product / Service
Zai Lab Ltd. - Key offerings
SWOT
16 Appendix
16.1 Scope of the report
16.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
16.3 Currency conversion rates for US$
Currency conversion rates for US$
16.4 Research methodology
Research methodology
16.5 Data procurement
Information sources
16.6 Data validation
Data validation
16.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
16.8 Data synthesis
Data synthesis
16.9 360 degree market analysis
360 degree market analysis
16.10 List of abbreviations
List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 6: Executive Summary - Chart on Market Segmentation by End-user
Exhibits 7: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits 8: Executive Summary - Chart on Incremental Growth
Exhibits 9: Executive Summary - Data Table on Incremental Growth
Exhibits 10: Executive Summary - Chart on Company Market Positioning
Exhibits 11: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 12: Overview on criticality of inputs and factors of differentiation
Exhibits 13: Overview on factors of disruption
Exhibits 14: Impact of drivers and challenges in 2024 and 2029
Exhibits 15: Parent Market
Exhibits 16: Data Table on - Parent Market
Exhibits 17: Market characteristics analysis
Exhibits 18: Value chain analysis
Exhibits 19: Offerings of companies included in the market definition
Exhibits 20: Market segments
Exhibits 21: Chart on Global - Market size and forecast 2024-2029 ($ million)
Exhibits 22: Data Table on Global - Market size and forecast 2024-2029 ($ million)
Exhibits 23: Chart on Global Market: Year-over-year growth 2024-2029 (%)
Exhibits 24: Data Table on Global Market: Year-over-year growth 2024-2029 (%)
Exhibits 25: Historic Market Size - Data Table on Global PARP (Poly ADP-Ribose Polymerase) Inhibitors Market 2019 - 2023 ($ million)
Exhibits 26: Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
Exhibits 27: Historic Market Size - End-user Segment 2019 - 2023 ($ million)
Exhibits 28: Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
Exhibits 29: Historic Market Size - Geography Segment 2019 - 2023 ($ million)
Exhibits 30: Historic Market Size - Country Segment 2019 - 2023 ($ million)
Exhibits 31: Five forces analysis - Comparison between 2024 and 2029
Exhibits 32: Bargaining power of buyers - Impact of key factors 2024 and 2029
Exhibits 33: Bargaining power of suppliers - Impact of key factors in 2024 and 2029
Exhibits 34: Threat of new entrants - Impact of key factors in 2024 and 2029
Exhibits 35: Threat of substitutes - Impact of key factors in 2024 and 2029
Exhibits 36: Threat of rivalry - Impact of key factors in 2024 and 2029
Exhibits 37: Chart on Market condition - Five forces 2024 and 2029
Exhibits 38: Chart on Distribution Channel - Market share 2024-2029 (%)
Exhibits 39: Data Table on Distribution Channel - Market share 2024-2029 (%)
Exhibits 40: Chart on Comparison by Distribution Channel
Exhibits 41: Data Table on Comparison by Distribution Channel
Exhibits 42: Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 43: Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 44: Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 45: Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 46: Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 47: Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 48: Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 49: Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 50: Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 51: Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Exhibits 52: Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 53: Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
Exhibits 54: Market opportunity by Distribution Channel ($ million)
Exhibits 55: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits 56: Chart on End-user - Market share 2024-2029 (%)
Exhibits 57: Data Table on End-user - Market share 2024-2029 (%)
Exhibits 58: Chart on Comparison by End-user
Exhibits 59: Data Table on Comparison by End-user
Exhibits 60: Chart on Ovarian cancer - Market size and forecast 2024-2029 ($ million)
Exhibits 61: Data Table on Ovarian cancer - Market size and forecast 2024-2029 ($ million)
Exhibits 62: Chart on Ovarian cancer - Year-over-year growth 2024-2029 (%)
Exhibits 63: Data Table on Ovarian cancer - Year-over-year growth 2024-2029 (%)
Exhibits 64: Chart on Breast cancer - Market size and forecast 2024-2029 ($ million)
Exhibits 65: Data Table on Breast cancer - Market size and forecast 2024-2029 ($ million)
Exhibits 66: Chart on Breast cancer - Year-over-year growth 2024-2029 (%)
Exhibits 67: Data Table on Breast cancer - Year-over-year growth 2024-2029 (%)
Exhibits 68: Chart on Others - Market size and forecast 2024-2029 ($ million)
Exhibits 69: Data Table on Others - Market size and forecast 2024-2029 ($ million)
Exhibits 70: Chart on Others - Year-over-year growth 2024-2029 (%)
Exhibits 71: Data Table on Others - Year-over-year growth 2024-2029 (%)
Exhibits 72: Market opportunity by End-user ($ million)
Exhibits 73: Data Table on Market opportunity by End-user ($ million)
Exhibits 74: Chart on Drug Class - Market share 2024-2029 (%)
Exhibits 75: Data Table on Drug Class - Market share 2024-2029 (%)
Exhibits 76: Chart on Comparison by Drug Class
Exhibits 77: Data Table on Comparison by Drug Class
Exhibits 78: Chart on Olaparib - Market size and forecast 2024-2029 ($ million)
Exhibits 79: Data Table on Olaparib - Market size and forecast 2024-2029 ($ million)
Exhibits 80: Chart on Olaparib - Year-over-year growth 2024-2029 (%)
Exhibits 81: Data Table on Olaparib - Year-over-year growth 2024-2029 (%)
Exhibits 82: Chart on Niraparib - Market size and forecast 2024-2029 ($ million)
Exhibits 83: Data Table on Niraparib - Market size and forecast 2024-2029 ($ million)
Exhibits 84: Chart on Niraparib - Year-over-year growth 2024-2029 (%)
Exhibits 85: Data Table on Niraparib - Year-over-year growth 2024-2029 (%)
Exhibits 86: Chart on Rucaparib - Market size and forecast 2024-2029 ($ million)
Exhibits 87: Data Table on Rucaparib - Market size and forecast 2024-2029 ($ million)
Exhibits 88: Chart on Rucaparib - Year-over-year growth 2024-2029 (%)
Exhibits 89: Data Table on Rucaparib - Year-over-year growth 2024-2029 (%)
Exhibits 90: Chart on Talazoparib - Market size and forecast 2024-2029 ($ million)
Exhibits 91: Data Table on Talazoparib - Market size and forecast 2024-2029 ($ million)
Exhibits 92: Chart on Talazoparib - Year-over-year growth 2024-2029 (%)
Exhibits 93: Data Table on Talazoparib - Year-over-year growth 2024-2029 (%)
Exhibits 94: Chart on Others - Market size and forecast 2024-2029 ($ million)
Exhibits 95: Data Table on Others - Market size and forecast 2024-2029 ($ million)
Exhibits 96: Chart on Others - Year-over-year growth 2024-2029 (%)
Exhibits 97: Data Table on Others - Year-over-year growth 2024-2029 (%)
Exhibits 98: Market opportunity by Drug Class ($ million)
Exhibits 99: Data Table on Market opportunity by Drug Class ($ million)
Exhibits 100: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 101: Chart on Market share By Geographical Landscape 2024-2029 (%)
Exhibits 102: Data Table on Market share By Geographical Landscape 2024-2029 (%)
Exhibits 103: Chart on Geographic comparison
Exhibits 104: Data Table on Geographic comparison
Exhibits 105: Chart on North America - Market size and forecast 2024-2029 ($ million)
Exhibits 106: Data Table on North America - Market size and forecast 2024-2029 ($ million)
Exhibits 107: Chart on North America - Year-over-year growth 2024-2029 (%)
Exhibits 108: Data Table on North America - Year-over-year growth 2024-2029 (%)
Exhibits 109: Chart on Europe - Market size and forecast 2024-2029 ($ million)
Exhibits 110: Data Table on Europe - Market size and forecast 2024-2029 ($ million)
Exhibits 111: Chart on Europe - Year-over-year growth 2024-2029 (%)
Exhibits 112: Data Table on Europe - Year-over-year growth 2024-2029 (%)
Exhibits 113: Chart on Asia - Market size and forecast 2024-2029 ($ million)
Exhibits 114: Data Table on Asia - Market size and forecast 2024-2029 ($ million)
Exhibits 115: Chart on Asia - Year-over-year growth 2024-2029 (%)
Exhibits 116: Data Table on Asia - Year-over-year growth 2024-2029 (%)
Exhibits 117: Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Exhibits 118: Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Exhibits 119: Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Exhibits 120: Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Exhibits 121: Chart on US - Market size and forecast 2024-2029 ($ million)
Exhibits 122: Data Table on US - Market size and forecast 2024-2029 ($ million)
Exhibits 123: Chart on US - Year-over-year growth 2024-2029 (%)
Exhibits 124: Data Table on US - Year-over-year growth 2024-2029 (%)
Exhibits 125: Chart on UK - Market size and forecast 2024-2029 ($ million)
Exhibits 126: Data Table on UK - Market size and forecast 2024-2029 ($ million)
Exhibits 127: Chart on UK - Year-over-year growth 2024-2029 (%)
Exhibits 128: Data Table on UK - Year-over-year growth 2024-2029 (%)
Exhibits 129: Chart on Germany - Market size and forecast 2024-2029 ($ million)
Exhibits 130: Data Table on Germany - Market size and forecast 2024-2029 ($ million)
Exhibits 131: Chart on Germany - Year-over-year growth 2024-2029 (%)
Exhibits 132: Data Table on Germany - Year-over-year growth 2024-2029 (%)
Exhibits 133: Chart on Canada - Market size and forecast 2024-2029 ($ million)
Exhibits 134: Data Table on Canada - Market size and forecast 2024-2029 ($ million)
Exhibits 135: Chart on Canada - Year-over-year growth 2024-2029 (%)
Exhibits 136: Data Table on Canada - Year-over-year growth 2024-2029 (%)
Exhibits 137: Chart on China - Market size and forecast 2024-2029 ($ million)
Exhibits 138: Data Table on China - Market size and forecast 2024-2029 ($ million)
Exhibits 139: Chart on China - Year-over-year growth 2024-2029 (%)
Exhibits 140: Data Table on China - Year-over-year growth 2024-2029 (%)
Exhibits 141: Chart on France - Market size and forecast 2024-2029 ($ million)
Exhibits 142: Data Table on France - Market size and forecast 2024-2029 ($ million)
Exhibits 143: Chart on France - Year-over-year growth 2024-2029 (%)
Exhibits 144: Data Table on France - Year-over-year growth 2024-2029 (%)
Exhibits 145: Chart on Italy - Market size and forecast 2024-2029 ($ million)
Exhibits 146: Data Table on Italy - Market size and forecast 2024-2029 ($ million)
Exhibits 147: Chart on Italy - Year-over-year growth 2024-2029 (%)
Exhibits 148: Data Table on Italy - Year-over-year growth 2024-2029 (%)
Exhibits 149: Chart on Spain - Market size and forecast 2024-2029 ($ million)
Exhibits 150: Data Table on Spain - Market size and forecast 2024-2029 ($ million)
Exhibits 151: Chart on Spain - Year-over-year growth 2024-2029 (%)
Exhibits 152: Data Table on Spain - Year-over-year growth 2024-2029 (%)
Exhibits 153: Chart on Japan - Market size and forecast 2024-2029 ($ million)
Exhibits 154: Data Table on Japan - Market size and forecast 2024-2029 ($ million)
Exhibits 155: Chart on Japan - Year-over-year growth 2024-2029 (%)
Exhibits 156: Data Table on Japan - Year-over-year growth 2024-2029 (%)
Exhibits 157: Chart on Mexico - Market size and forecast 2024-2029 ($ million)
Exhibits 158: Data Table on Mexico - Market size and forecast 2024-2029 ($ million)
Exhibits 159: Chart on Mexico - Year-over-year growth 2024-2029 (%)
Exhibits 160: Data Table on Mexico - Year-over-year growth 2024-2029 (%)
Exhibits 161: Market opportunity By Geographical Landscape ($ million)
Exhibits 162: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 163: Impact of drivers and challenges in 2024 and 2029
Exhibits 164: Overview on criticality of inputs and factors of differentiation
Exhibits 165: Overview on factors of disruption
Exhibits 166: Impact of key risks on business
Exhibits 167: Companies covered
Exhibits 168: Company ranking index
Exhibits 169: Matrix on companies position and classification
Exhibits 170: AbbVie Inc. - Overview
Exhibits 171: AbbVie Inc. - Product / Service
Exhibits 172: AbbVie Inc. - Key news
Exhibits 173: AbbVie Inc. - Key offerings
Exhibits 174: SWOT
Exhibits 175: Allarity Therapeutics Inc. - Overview
Exhibits 176: Allarity Therapeutics Inc. - Product / Service
Exhibits 177: Allarity Therapeutics Inc. - Key offerings
Exhibits 178: SWOT
Exhibits 179: AstraZeneca Plc - Overview
Exhibits 180: AstraZeneca Plc - Product / Service
Exhibits 181: AstraZeneca Plc - Key news
Exhibits 182: AstraZeneca Plc - Key offerings
Exhibits 183: SWOT
Exhibits 184: Bayer AG - Overview
Exhibits 185: Bayer AG - Business segments
Exhibits 186: Bayer AG - Key news
Exhibits 187: Bayer AG - Key offerings
Exhibits 188: Bayer AG - Segment focus
Exhibits 189: SWOT
Exhibits 190: BeiGene Ltd. - Overview
Exhibits 191: BeiGene Ltd. - Business segments
Exhibits 192: BeiGene Ltd. - Key offerings
Exhibits 193: BeiGene Ltd. - Segment focus
Exhibits 194: SWOT
Exhibits 195: Daiichi Sankyo Co. Ltd. - Overview
Exhibits 196: Daiichi Sankyo Co. Ltd. - Product / Service
Exhibits 197: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibits 198: SWOT
Exhibits 199: Everest Pharmaceuticals Ltd. - Overview
Exhibits 200: Everest Pharmaceuticals Ltd. - Product / Service
Exhibits 201: Everest Pharmaceuticals Ltd. - Key offerings
Exhibits 202: SWOT
Exhibits 203: GlaxoSmithKline Plc - Overview
Exhibits 204: GlaxoSmithKline Plc - Business segments
Exhibits 205: GlaxoSmithKline Plc - Key news
Exhibits 206: GlaxoSmithKline Plc - Key offerings
Exhibits 207: GlaxoSmithKline Plc - Segment focus
Exhibits 208: SWOT
Exhibits 209: IMPACT Therapeutics - Overview
Exhibits 210: IMPACT Therapeutics - Product / Service
Exhibits 211: IMPACT Therapeutics - Key offerings
Exhibits 212: SWOT
Exhibits 213: Jeil Pharmaceuticals Co. Ltd. - Overview
Exhibits 214: Jeil Pharmaceuticals Co. Ltd. - Product / Service
Exhibits 215: Jeil Pharmaceuticals Co. Ltd. - Key offerings
Exhibits 216: SWOT
Exhibits 217: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
Exhibits 218: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
Exhibits 219: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
Exhibits 220: SWOT
Exhibits 221: Merck and Co. Inc. - Overview
Exhibits 222: Merck and Co. Inc. - Business segments
Exhibits 223: Merck and Co. Inc. - Key news
Exhibits 224: Merck and Co. Inc. - Key offerings
Exhibits 225: Merck and Co. Inc. - Segment focus
Exhibits 226: SWOT
Exhibits 227: Ono Pharmaceutical Co. Ltd. - Overview
Exhibits 228: Ono Pharmaceutical Co. Ltd. - Product / Service
Exhibits 229: Ono Pharmaceutical Co. Ltd. - Key offerings
Exhibits 230: SWOT
Exhibits 231: Pfizer Inc. - Overview
Exhibits 232: Pfizer Inc. - Product / Service
Exhibits 233: Pfizer Inc. - Key news
Exhibits 234: Pfizer Inc. - Key offerings
Exhibits 235: SWOT
Exhibits 236: Zai Lab Ltd. - Overview
Exhibits 237: Zai Lab Ltd. - Product / Service
Exhibits 238: Zai Lab Ltd. - Key offerings
Exhibits 239: SWOT
Exhibits 240: Inclusions checklist
Exhibits 241: Exclusions checklist
Exhibits 242: Currency conversion rates for US$
Exhibits 243: Research methodology
Exhibits 244: Information sources
Exhibits 245: Data validation
Exhibits 246: Validation techniques employed for market sizing
Exhibits 247: Data synthesis
Exhibits 248: 360 degree market analysis
Exhibits 249: List of abbreviations

Executive Summary

The following companies are recognized as the key players in the global parp (Poly ADP-Ribose Polymerase) inhibitors market: AbbVie Inc., Allarity Therapeutics Inc., Artios Pharma, AstraZeneca Plc, Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Everest Pharmaceuticals Ltd., GlaxoSmithKline Plc, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Services Inc., Karyopharm Therapeutics Inc., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Repare Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and Zai Lab Ltd..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is extensive ongoing research."

According to the report, one of the major drivers for this market is the expanded application of parp inhibitors.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Allarity Therapeutics Inc.
  • Artios Pharma
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Everest Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals Co. Ltd.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Johnson and Johnson Services Inc.
  • Karyopharm Therapeutics Inc.
  • Merck and Co. Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Repare Therapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zai Lab Ltd.

Related Topics

Related Reports

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025 - Product Image

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025 - Product Image

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Poly(ADP-ribose) Polymerase Inhibitors - Pipeline Insight, 2025 - Product Image

Poly(ADP-ribose) Polymerase Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 80 Pages
  • Global
From
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor - Pipeline Insight, 2025 - Product Image

Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 120 Pages
  • Global
From
Poly Polymerase Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Poly Polymerase Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 86 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.